SCHEDULE 13D/A: RA Capital Management Amends iTeos Therapeutics Stake, Disclosing Significant Share Sales

RA Capital Management and its affiliates have filed an amendment to their Schedule 13D, revealing a reduced beneficial ownership in iTeos Therapeutics, Inc. to 9.9% following recent open market sales.

Summary

• This document is Amendment No. 2 to a Schedule 13D filing by RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") concerning their beneficial ownership in iTeos Therapeutics, Inc.
• The Reporting Persons collectively beneficially own 4,163,276 shares of iTeos Therapeutics common stock, representing 9.9% of the outstanding class.
• RA Capital Healthcare Fund, L.P. beneficially owns 3,514,493 shares, representing 8.4% of the class.
• These percentages are calculated based on 38,273,795 shares of iTeos Therapeutics common stock reported as outstanding as of April 22, 2025.
• The ownership includes 113,845 shares of common stock and pre-funded warrants exercisable for up to 5,057,285 shares directly held by RA Capital Healthcare Fund, L.P., and 648,783 shares directly held by RA Capital Nexus Fund, L.P.
• Pre-Funded Warrants contain a provision that prevents their exercise if it would result in ownership exceeding 9.99% of the outstanding common stock.
• During the past sixty days, significant open market sales were executed by the Reporting Persons:
• RA Capital Healthcare Fund, L.P. sold 653,729 shares on May 12, 2025, at a weighted average price of $6.79 per share (ranging from $6.75 to $7.01).
• RA Capital Healthcare Fund, L.P. sold 1,983,805 shares on May 13, 2025, at a weighted average price of $8.09 per share (ranging from $8.00 to $8.37).
• RA Capital Nexus Fund, L.P. sold 248,895 shares on May 13, 2025, at a weighted average price of $8.09 per share (ranging from $8.00 to $8.37).

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to the significant reduction in beneficial ownership by a major institutional investor through open market sales, which can be interpreted as a lack of confidence or a strategic exit from a portion of the position.

Positives

• RA Capital Management and its affiliates maintain a significant, albeit reduced, stake in iTeos Therapeutics, indicating continued, though potentially re-evaluated, interest in the company.

Negatives

• The Reporting Persons, primarily RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., have significantly reduced their holdings in iTeos Therapeutics through open market sales totaling 2,886,429 shares.
• The beneficial ownership percentage for RA Capital Management, Peter Kolchinsky, and Rajeev Shah has decreased to 9.9%, implying a substantial divestment from their previous position.

Risks

• The document does not explicitly state risks related to iTeos Therapeutics, but the significant sales by a major institutional investor could be interpreted by the market as a negative signal or a perceived increase in risk by the selling party, potentially impacting investor confidence.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding iTeos Therapeutics, Inc. or the Reporting Persons' future investment intentions beyond the disclosed beneficial ownership.

Industry Context

This filing reflects a portfolio adjustment by a prominent healthcare-focused investment firm, RA Capital Management, in a biotechnology company, iTeos Therapeutics. While the specific reasons for the sales are not disclosed, such significant divestments by a major investor can sometimes signal a re-evaluation of the company's prospects within the competitive and often volatile biotechnology sector, or a broader portfolio rebalancing strategy.

Stakeholder Impact

• Shareholders: Existing shareholders may react negatively to the news of a major institutional investor reducing its stake, potentially leading to downward pressure on the stock price. New investors might view this as a signal to reconsider investment.
• Company Management: The company's management might face questions regarding the reasons for the significant divestment by a prominent investor, potentially impacting investor relations and future capital-raising efforts.

Key Dates

Recommendation

Keywords

RA Capital Management, iTeos Therapeutics, Schedule 13D/A, Beneficial Ownership, Share Sales, Institutional Investor, Biotechnology, Healthcare Investment, SEC Filing, Peter Kolchinsky, Rajeev Shah